Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention
Open Access
- 22 May 2026
- journal article
- Published by Elsevier in JACC: Asia
- Vol. 6 (7) , 1095-1105
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences
This publication has 22 references indexed in Scilit:
- Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-Segment Elevation Myocardial InfarctionJACC, 2022
- Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus After Anterior ST-Segment Elevation Myocardial InfarctionJACC: Cardiovascular Interventions, 2022
- Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2022
- Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarctionAmerican Heart Journal, 2020
- Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2019
- Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary SyndromeJACC, 2019
- 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial InfarctionJACC, 2016
- A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial)The American Journal of Cardiology, 2013
- Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialThe Lancet, 2011
- Enoxaparin in Primary and Facilitated Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2010